Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

Zydus receives USFDA approval for cevimeline hydrochloride capsules

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36

Roche shareholders back full slate of proposals, approve record dividend increase

Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4